



Department
of Health



NHS public health functions agreement 2015-16

Service specification No.7

Hib/Men C vaccination programme

<p>Title: NHS public health functions agreement 2015-16, Service specification No.7 Hib/Men C vaccination programme</p>
<p>Author: Directorate/ Division/ Branch acronym/ cost centre PHD/ IH&PHD/ PHPSU/ 10100</p>
<p>Document Purpose: Policy</p>
<p>Publication date: December 2014</p>
<p>Target audience: NHS England regional directors, NHS England area directors</p>
<p>Contact details: Public health policy and strategy unit phpsu@dh.gsi.gov.uk</p>

You may re-use the text of this document (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government-licence/

© Crown copyright 2014

Published to gov.uk, in PDF format only.

www.gov.uk/dh

NHS England Publications Gateway Reference 02579

NHS public health functions agreement 2015-16

Service specification No.7

Hib/Men C Immunisation programme

Prepared by Public Health England

Contents

Service specification No.7	5
1. Purpose of Hib/MenC immunisation programme	6
2. Population needs.....	7
Background	7
<i>Haemophilus influenzae</i> type b (Hib).....	7
Meningococcal C (Men C)	7
Hib/Men C vaccine – key details.....	8
3. Scope	9
Aims.....	9
Objectives.....	9
Direct health outcomes	9
Baseline vaccine coverage	9
4. Service description / care pathway	10
Local service delivery	10
Target population.....	10
Vaccine schedule	10
Further information on scheduling for risk groups is available in the relevant chapters of the Green Book. Vaccine ordering.....	11

Service specification No.7

This is a service specification within Annex C of the 'NHS public health functions agreement 2015-16 (the '2015-16 agreement') published in December 2014.

This service specification is to be applied by NHS England in accordance with the 2015-16 agreement. This service specification is not intended to replicate, duplicate or supersede any other legislative provisions that may apply.

Where a specification refers to any other published document or standard, it refers to the document or standard as it existed at the date when the 2015-16 agreement was made between the Secretary of State and NHS England Board. Any changes in other published documents or standards may have effect for the purposes of the 2015-16 agreement in accordance with the procedures described in Chapter 3 of the 2015-16 agreement

Service specifications should be downloaded in order to ensure that commissioners and providers refer to the latest document that is in effect.

The 2015-16 agreement including all service specifications within Annex C is available at www.gov.uk (search for 'commissioning public health').

This service specification is not intended to replicate, duplicate or supersede any other legislative provisions that may apply. It must always be read in conjunction with the core service specification <https://www.gov.uk/government/publications/public-health-commissioning-in-the-nhs-2015-to-2016> and the online version of the Green

Book: <https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book>

1. Purpose of Hib/MenC immunisation programme

- 1.1. This document relates to the Hib/MenC booster vaccine that protects children against Haemophilus Influenza Type b (Hib) and Meningococcal C (Men C) infections. This immunisation is part of the national childhood immunisation programme which aims to prevent children from catching vaccine preventable diseases that are associated with significant mortality and morbidity. The purpose of the service specification is to enable NHS England' to commission Hib/MenC immunisation services to a standard which will minimise infections and outbreaks caused by these organisms. This means achieving high levels of coverage across England as well as within upper tier local government areas and within the context of populations with protected characteristics as defined by the Equality Act 2010.
- 1.2. This specification provides a brief overview of the vaccines including the disease they protect against, the context, evidence base, and wider health outcomes, and should be read alongside the core service specification which underpins national and local commissioning practices and service delivery.
- 1.3. This specification will promote a consistent and equitable approach to the commissioning and delivery of the Hib/MenC vaccines across England. However, it is important to note that this programme can change and evolve in the light of emerging best practice and scientific evidence. NHS England and providers will be required to reflect these changes accordingly in a timely way as directed by the national schedule.
- 1.4. [Immunisation against infectious disease](#) (known as 'The Green Book'), as issued by Public Health England provides guidance and has the latest information on vaccines and vaccination procedures for all the vaccine preventable infectious diseases that may occur in the UK. This service specification must be read in conjunction with the core service specification, the online version of the Green Book, related official public health letters and reflected in the commissioning of immunisation programmes. This specification must also be read in conjunction with additional evidence, guidance and literature issued by the Joint Committee on Vaccination and Immunisation (JCVI). <https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation>
- 1.5. This service specification is not designed to replicate, duplicate or supersede any relevant legislative provisions that may apply e.g. the Health and Social Care Act 2012. The specification will be reviewed and amended in line with any new recommendations or guidance, and in line with reviews of the Section 7A agreement.

2. Population needs

Background

- 2.1. The Hib/MenC booster is offered routinely at 12 months of age as part of the UK childhood immunisation schedule and it provides protection against infections caused by the following bacterial infections:
 - *Haemophilus influenzae* type b (Hib)
 - Meningococcal C (Men C)
- 2.2. The vaccine boosts the protection a child gets from the first course of Hib vaccine at two, three and four months of age, and the MenC vaccine at three months. The booster is designed to extend the protection offered in infancy during the period of highest risk of these infections (up to five years of age). The Hib/MenC booster in the second year of life was introduced into the routine childhood immunisation programme in 2006, because studies had shown that protection after the infant course declined quite quickly. The vaccine, has a strong evidence base and is highly effective in protecting against these serious diseases, which can still be found within the UK and beyond.

Haemophilus influenzae type b (Hib)

- 2.3. Hib is an infection that can cause invasive disease such as septicaemia, epiglottitis, septic arthritis, pneumonia and meningitis, all of which can be fatal. Individuals can carry Hib bacteria in their nose and throat without showing signs of the disease. Hib is spread through coughing, sneezing or close contact with a carrier. Since the introduction of Hib immunisation in the UK, disease incidence has fallen. In 2010 there were only 30 reported cases of confirmed invasive Hib infection in the England and Wales.

Meningococcal C (Men C)

- 2.4. Meningococcal disease results from bacterial infection, the route of transmission is through droplets or respiratory secretions (e.g. coughing and sneezing). There is a marked seasonal variation in meningococcal disease rates, with peak levels in the winter months, usually declining to low levels by late summer. There are at least 13 known serogroups of meningococcal disease. Of these, prior to the introduction of the vaccine, only two serogroups B and C – were of major public health importance to the UK.
- 2.5. Meningococcal infection can cause meningitis (inflammation of the membranes surrounding the brain) and septicaemia (blood poisoning). Septicaemia may occur alone or as part of an attack of meningitis. Meningococcal infection is relatively rare affecting 5 in 100,000 people a year in the UK. Approximately one in ten people who develop meningococcal disease will die. The highest risk of meningococcal disease is in the under one-year-old group, with the one to five age group following closely. The next highest risk group is young people aged 15 to 19 years.

- 2.6. Since the introduction of MenC vaccine the number of laboratory confirmed group C cases fell by over 90% in those age groups immunised (Salisbury et al, 2001; Trotter et al, 2004) and by two-thirds in other age groups as a result of herd immunity (Trotter et al, 2003). In 1998/9 – the year before vaccine was introduced – there were 955 serogroup C cases reported. There are now around 20 cases per year.

Hib/Men C vaccine – key details

- a combined Hib/Men C booster vaccine is given at 12 months. It builds on the primary Hib and MenC vaccines given as part of the childhood immunisation programme.
- it has a strong evidence base, an excellent safety profile and is highly effective.

3. Scope

Aims

- 3.1. The aim of the Hib/MenC vaccination programme is to boost children's immunity against Hib and meningococcal C disease – both associated with significant mortality and morbidity.

Objectives

- 3.2. The aim will be achieved by delivering a population-wide immunisation programme that:
- identifies the eligible population based on the target population set out in the Green Book and ensures optimal coverage
 - is safe, effective, timely and of a high quality and is independently monitored
 - is delivered and supported by suitably trained, competent healthcare professionals who participate in recognised ongoing training and development in line with national standards
 - delivers, manages and stores vaccine in accordance with national guidance
 - is supported by regular and accurate data collection using the appropriate returns.

Direct health outcomes

- 3.3. The Hib/MenC vaccination programme aims to
- Protect the health of individuals and the wider population
 - reduce the number of preventable infections and their onward transmission
 - achieve high coverage across all groups identified
 - minimise adverse physical/psychological/clinical aspects of immunisation (e.g. anxiety, adverse reactions).

Baseline vaccine coverage

- 3.4. Local services must ensure they maintain and improve current immunisation coverage (with reference to vaccine coverage public health outcomes framework indicators) with the aim of 100% of relevant individuals being offered immunisation in accordance with the Green Book and other official DH/PHE guidance. This includes performance indicators and key deliverables that are set out in Annex B of NHS Public Health Functions Agreement (Section 7A) for 2015-2016.

4. Service description / care pathway

Local service delivery

- 4.1. This section of the document specifies the high-level operational elements of the Hib/MenC vaccine programme, based on best practice that the NHS England must use to inform local commissioning, contracts and service delivery. There is also scope to enable NHS England and providers to enhance and build on specifications to incorporate national or local service aspirations that may include increasing local innovation in service delivery. However, it is essential, in order to promote a nationally aligned, high-quality programme focusing on improved outcomes, increasing coverage and local take-up that all core elements that are set out in the core service specification are included in contracts and specifications.

Target population

- 4.2. NHS England must ensure that Hib/MenC immunisation is available to:
- all children both registered and unregistered with a GP, as part of the childhood immunisation programme's primary immunisation course, up to the age of ten years
 - there is no upper age limit for vaccination, and those at particular risk may require vaccination with a different product, even if above the age of the current national programme. Protection against Hib and Men C should be offered routinely to unvaccinated or partially vaccinated individuals up to the age of ten years, or for those at particular risk as outlined in the [Green Book](#) chapters 16, 22 and 7
 - address poor uptake for the services set out in the S7A agreement, where local delivery is lower than the key deliverables set out in the S7A agreement and in accordance with the objective to reduce the variation in local levels of performance.

In addition:

- the vaccination status of every child must be checked at each visit (for example the pre-school visit for booster vaccines) and missing doses of relevant immunisations offered as appropriate to ensure that everyone has completed an age-appropriate course.

Vaccine schedule

- 4.3.
- One dose at 12 months of age (along with the PCV booster and MMR)
 - In order to provide early protection, providers must aim to complete the schedule at near as possible to the recommended ages.
 - Sufficient immunisation appointments must be available so that children can receive vaccinations on time – waiting lists are not acceptable.

- 4.4. Further information on scheduling for risk groups is available in the relevant chapters of the Green Book.

Vaccine ordering

- 4.5. All centrally procured vaccines must be ordered via the ImmForm online ordering system, details of which are given in the core specification.